Alto Neuroscience Adds 'Intriguing' Depression Asset Via Over $100 Million Deal

Why is Procter & Gamble cutting 7,000 jobs? How did Boeing avoid prosecution for 737 Max crashes? What impact did Trump-Xi trade talks have on markets? Why are U.S. jobless claims rising recently? How are tariffs affecting U.S. manufacturing costs? What caused Tesla’s sales decline in China? Why did Amazon invest $10B in AI data centers?

Alto Neuroscience Adds 'Intriguing' Depression Asset Via Over $100 Million Deal

benzinga.com/news/health-care/25/06/45756266/alto-neuroscience-adds-intriguing-depression-asset-via-over-100-million-deal

On Tuesday, Alto Neuroscience, Inc. (NASDAQ:ANRO) announced an asset purchase agreement with Chase Therapeutics Corporation for a portfolio of dopamine agonist drug combinations for treatment-resistant depression (TRD), generally defined as a failure on two or more antidepressants.
Alto…

This story appeared on benzinga.com, 2025-06-03 18:48:29.